{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deformity%3B+Skin&page=5",
    "query": {
      "condition": "Deformity; Skin",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 1849,
    "total_pages": 185,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deformity%3B+Skin&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deformity%3B+Skin&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T10:54:59.925Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02156674",
      "title": "Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Maroteaux-Lamy Syndrome"
      ],
      "interventions": [
        {
          "name": "Naglazyme®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-01-26",
      "completion_date": "2019-12-01",
      "has_results": true,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-10-20T10:54:59.925Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02156674"
    },
    {
      "nct_id": "NCT03840928",
      "title": "PatientSpot Formerly Known as ArthritisPower",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatoid Arthritis",
        "Ankylosing Spondylitis",
        "Fibromyalgia",
        "Gout",
        "Crohn Disease",
        "Juvenile Idiopathic Arthritis",
        "Lupus Erythematosus",
        "Myositis",
        "Osteoarthritis",
        "Osteoporosis",
        "Psoriasis",
        "Psoriatic Arthritis",
        "Scleroderma",
        "Dermatomyositis",
        "Inflammatory Bowel Diseases",
        "Polymyositis",
        "Axial Spondyloarthritis",
        "Diffuse Idiopathic Skeletal Hyperostosis",
        "Polymyalgia Rheumatica",
        "Giant Cell Arteritis",
        "Temporal Arteritis",
        "Wegener",
        "Relapsing Polychondritis",
        "Undifferentiated Connective Tissue Disease",
        "Spinal Cord Injuries",
        "Alzheimer Disease",
        "Amyotrophic Lateral Sclerosis",
        "Ataxia",
        "Bell Palsy",
        "Brain Tumor",
        "Cerebral Aneurysm",
        "Epilepsy",
        "Guillain-Barre Syndrome",
        "Headache",
        "Head Injury",
        "Hydrocephalus",
        "Lumbar Disc Disease",
        "Meningitis",
        "Multiple Sclerosis",
        "Muscular Dystrophy",
        "Neurocutaneous Syndromes",
        "Parkinson Disease",
        "Stroke",
        "Cluster Headache",
        "Tension-Type Headache",
        "Chronic Obstructive Pulmonary Disease",
        "Asthma",
        "Lung Cancer",
        "Cystic Fibrosis",
        "Sleep Apnea",
        "Eczema",
        "Alopecia",
        "Chronic Inflammation",
        "Unstable Angina",
        "Heart Attack",
        "Heart Failure",
        "Arrythmia",
        "Valve Heart Disease",
        "High Blood Pressure",
        "Congenital Heart Disease",
        "Peripheral Arterial Disease",
        "Diabetes",
        "Chronic Liver Disease",
        "Obesity"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Global Healthy Living Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 40000,
      "start_date": "2015-04-01",
      "completion_date": "2025-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-13",
      "last_synced_at": "2026-10-20T10:54:59.925Z",
      "location_count": 1,
      "location_summary": "Upper Nyack, New York",
      "locations": [
        {
          "city": "Upper Nyack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03840928"
    },
    {
      "nct_id": "NCT06389136",
      "title": "A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Upadacitinib 15mg Dose",
          "type": "DRUG"
        },
        {
          "name": "Dupilumab 300mg Dose",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib 30mg Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "63 Years",
        "sex": "ALL",
        "summary": "18 Years to 63 Years"
      },
      "enrollment_count": 184,
      "start_date": "2024-06-14",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-20T10:54:59.925Z",
      "location_count": 84,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06389136"
    },
    {
      "nct_id": "NCT04008849",
      "title": "A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inherited Metabolic Disorders (IMD)"
      ],
      "interventions": [
        {
          "name": "Safety and efficacy assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Magenta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "Up to 16 Years"
      },
      "enrollment_count": 3,
      "start_date": "2019-05-21",
      "completion_date": "2020-10-08",
      "has_results": false,
      "last_update_posted_date": "2021-03-15",
      "last_synced_at": "2026-10-20T10:54:59.925Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04008849"
    },
    {
      "nct_id": "NCT01019148",
      "title": "Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 70,
      "start_date": "2009-11-10",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-20T10:54:59.925Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01019148"
    },
    {
      "nct_id": "NCT00001164",
      "title": "Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy",
        "Muscular Dystrophy",
        "Retinal Degeneration",
        "Skin Diseases",
        "Virus Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "1978-07",
      "completion_date": "2000-06",
      "has_results": false,
      "last_update_posted_date": "2008-03-05",
      "last_synced_at": "2026-10-20T10:54:59.925Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001164"
    },
    {
      "nct_id": "NCT04023084",
      "title": "Response of Children With Atopic Dermatitis (Eczema) to Eucrisa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Eczema"
      ],
      "interventions": [
        {
          "name": "Crisaborole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Months to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2019-10-03",
      "completion_date": "2022-02-11",
      "has_results": false,
      "last_update_posted_date": "2022-07-19",
      "last_synced_at": "2026-10-20T10:54:59.925Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04023084"
    },
    {
      "nct_id": "NCT04571658",
      "title": "NEPTUNE Match Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nephrotic Syndrome in Children",
        "Focal Segmental Glomerulosclerosis",
        "Minimal Change Disease",
        "Minimal Change Nephrotic Syndrome",
        "Membranous Nephropathy",
        "FSGS",
        "MCD",
        "MCD - Minimal Change Disease",
        "Alport Syndrome"
      ],
      "interventions": [
        {
          "name": "Communication",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "1 Year to 80 Years"
      },
      "enrollment_count": 375,
      "start_date": "2022-05-02",
      "completion_date": "2029-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-20T10:54:59.925Z",
      "location_count": 16,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04571658"
    },
    {
      "nct_id": "NCT00035334",
      "title": "Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Secondary (AA) Amyloidosis",
        "Rheumatoid Arthritis",
        "Nephrotic Syndrome",
        "Familial Mediterranean Syndrome",
        "Kidney Diseases",
        "Gastrointestinal Diseases"
      ],
      "interventions": [
        {
          "name": "NC-503 (Anti-amyloidotic (AA) Agent)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bellus Health Inc. - a GSK company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2001-10",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2006-02-14",
      "last_synced_at": "2026-10-20T10:54:59.925Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035334"
    },
    {
      "nct_id": "NCT06846398",
      "title": "A Phase 2 in Adult Subjects With Hereditary Angioedema",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "BW-20805",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Argo Biopharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2025-02-28",
      "completion_date": "2028-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-20T10:54:59.925Z",
      "location_count": 5,
      "location_summary": "Silver Spring, Maryland • St Louis, Missouri • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06846398"
    }
  ]
}